0001193125-26-187243
SEC filingQuince Therapeutics regained Nasdaq compliance with the $1.00 minimum bid price requirement but remains non-compliant with the $50M MVLS requirement until September 14, 2026.
Quince Therapeutics received notification on April 27, 2026, confirming compliance with Nasdaq's minimum bid price rule after 10 consecutive business days of closing prices at or above $1.00 per share, resolving prior deficiency concerns and stabilizing listing status on that front. However, the company continues to face challenges with the market value of listed securities requirement, having previously fallen below the $50 million threshold over 30 consecutive business days. It now has until September 14, 2026—a 180-calendar-day extension—to meet this standard, highlighting ongoing risks to its Nasdaq Global Select Market listing if market conditions do not improve.